These cancer patients write their own story
They hurt. They weep. They fly. They soar above the thunderheads. They plunge back to earth. They hold fast to their lovers and their children. They bruise. They burn. They heal. Cancer is not a...
They hurt. They weep. They fly. They soar above the thunderheads. They plunge back to earth. They hold fast to their lovers and their children. They bruise. They burn. They heal. Cancer is not a...
Acute myeloid leukemia, or AML, is the most common acute blood cancer in adults — and one of the most difficult to treat. Scientists at Oregon Health & Science University have discovered a...
Inherited mutations that increase the risk of developing a dangerous blood cancer are more common than previously appreciated, a new study reveals. Researchers analyzed acute myeloid leukemia...
Using genetic information to match patients to targeted therapies may improve survival in people with a fast-moving leukemia. Because acute myeloid leukemia is such a fast-moving and deadly cancer,...
OHSU Knight Cancer Institute scientists have identified key gene networks and signaling pathways that cancerous cells in acute myeloid leukemia use to resist treatment with the drug venetoclax, one...
The Beat AML clinical trial has matched 250 study participants to targeted treatments for acute myeloid leukemia – with promising early results. Regulators were wary of the complicated study...
A $10 million gift from The Harry T. Mangurian Jr. Foundation will help The Leukemia & Lymphoma Society expand the Beat AML Master Trial underway at the OHSU Knight Cancer Institute and other...
The best available treatment for acute myeloid leukemia is a drug combination established more than 30 years ago. And today less than a third of newly diagnosed AML patients survive beyond five...
Nine drug companies and six universities have now joined an unusual collaboration to break the logjam in research on acute myeloid leukemia (AML), a blood cancer lacking effective treatments....